Ophthotech Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
210,596.00
463,560.00
296,592.00
289,278.00
166,972.00
Total Accounts Receivable
-
960.00
4,389.00
3,531.00
1,387.00
Other Current Assets
6,804.00
9,105.00
5,504.00
3,078.00
3,146.00
Total Current Assets
217,400.00
473,625.00
306,485.00
295,887.00
171,505.00
Net Property, Plant & Equipment
27.00
1,555.00
3,466.00
3,281.00
518.00
Total Investments and Advances
-
282.00
95,298.00
-
-
Other Assets
255.00
100.00
489.00
462.00
24.00
Total Assets
217,682.00
498,370.00
428,851.00
299,630.00
175,576.00
Accounts Payable
3,810.00
8,707.00
12,018.00
12,032.00
5,051.00
Other Current Liabilities
2,485.00
11,124.00
25,487.00
53,886.00
7,484.00
Total Current Liabilities
6,295.00
19,831.00
37,505.00
65,918.00
12,535.00
Long-Term Debt
41,667.00
125,000.00
125,000.00
125,000.00
125,000.00
Deferred Taxes
-
22,808.00
23,113.00
-
3,529.00
Other Liabilities
-
206,418.00
206,399.00
203,330.00
-
Total Liabilities
47,962.00
351,249.00
368,904.00
394,248.00
137,535.00
Common Equity (Total)
169,720.00
147,121.00
59,947.00
94,618.00
38,041.00
Total Shareholders' Equity
169,720.00
147,121.00
59,947.00
94,618.00
38,041.00
Total Equity
169,720.00
147,121.00
59,947.00
94,618.00
38,041.00
Liabilities & Shareholders' Equity
217,682.00
498,370.00
428,851.00
299,630.00
175,576.00

About Ophthotech

View Profile
Address
One Penn Plaza
New York New York 10119
United States
Employees -
Website http://www.ophthotech.com
Updated 09/14/2018
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.